

accelerate

innovate

collaborate

WELCOME

Creating Consensus Science: New Tools and Tactics for Next-Gen Drug Development

November 30 – December 1, 2011
Silver Spring, Maryland

Creating Consensus Science: New Tools and Tactics for Next-Gen Drug Development

Sponsored by



Creating Innovative Collaborations



Dr. Ray Woosley, Governor Janet Napolitano, Dr. Janet Woodcock, Rep. Jim Kolbe
December 2005

Creating Consensus



Predictive Safety Testing Consortium
DRUG SAFETY



Patient-Reported Outcome Consortium
DRUG EFFECTIVENESS



Coalition Against Major Diseases
**UNDERSTANDING DISEASES
OF THE BRAIN**



Polycystic Kidney Disease Consortium
NEW IMAGING TESTS



Critical Path to TB Drug Regimens
TESTING DRUG COMBINATIONS



- ☐ ***Biomarkers***
- ☐ ***Patient
Reported
Outcomes***
- ☐ ***Disease
Progression
Models***
- ☐ ***Data
Standards***



Collaborators

Industry



Partners



Patients



Research



Government



C-Path and CDISC Collaborations



C-Path – FDA Qualification




CAMD – *Alzheimer's, Parkinson's*
PKD – *Polycystic Kidney Disease*
PSTC – *Safety Testing*
CPTR – *Tuberculosis*



CDISC – Data Standards



The Value of Collaboration



“R&D is still performing, but it’s getting harder. For most companies, the challenges go beyond simply organisational fixes. The next wave to boost productivity is more collaboration. We see an unprecedented appetite by chief executives to work with each other in non-competitive areas.”

Deloitte partner Julian Remnant
Financial Times, November 21, 2011

Keynote Speaker



Margaret Hamburg, MD

Commissioner,
U.S. Food and Drug Administration

Creating Consensus Science: New Tools and Tactics for Next-Gen Drug Development

Sponsored by

